Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Department of Anesthesia and Intensive Care, Ospedale Policlinico San Martino, IRCCS for Oncology and Neuroscience, Genoa, Italy.
Respir Physiol Neurobiol. 2020 Sep;280:103492. doi: 10.1016/j.resp.2020.103492. Epub 2020 Jul 10.
In December 2019, an outbreak of severe pneumonia was reported in Wuhan, China. Later described as COVID-19 (coronavirus disease 2019), this infection caused by a virus from the Coronaviridae family (SARS-CoV-2) has spread globally. Effective therapies for this new disease are urgently needed. In this short communication, we will evaluate the use of corticosteroids as an adjunctive pharmacological therapy in the management of COVID-19 and describe its pros and cons in light of the latest available evidence.
2019 年 12 月，中国武汉报告了一起严重肺炎疫情。这种由冠状病毒科（SARS-CoV-2）病毒引起的感染后来被描述为 COVID-19（2019 年冠状病毒病），已在全球范围内传播。迫切需要针对这种新疾病的有效疗法。在本短讯中，我们将评估皮质类固醇作为 COVID-19 管理辅助药物治疗的用途，并根据最新可用证据说明其优缺点。
